Objectives: To describe the clinical, perimetric, and electroretinographic (ERG) results of 4 patients with cone dysfunction following irofulven treatment including the histopathologic and immunocytochemical features of one patient's retinas.
A
RETINAL TOXIC REACTION may result during treatment of cancer. Cisplatin treatment can cause abnormal cone 1 or cone and rod 2, 3 ERG responses, transient cortical blindness, papilledema, and retrobulbar neuritis. 4, 5 High-dose carboplatin therapy can produce pigmentary maculopathy, optic neuropathy, chorioretinitis, and transient cortical blindness. 6, 7 Paclitaxel, often combined with carboplatin therapy, can cause photopsias and transient scotomas. [8] [9] [10] [11] Better therapies are needed for recurrent ovarian cancer. The goal is to maximize benefit and simultaneously minimize toxic effects, since therapy for recurrent disease is mainly palliative. New drugs require particular scrutiny for new or unusual toxic reactions such as retinal damage.
Irofulven (6-hydroxymethylacylfulvene, MGI 114; MGI Pharma, Inc, Bloomington, Minn), an illudin S derivative from the jack-o-lantern mushroom (Omphalotus illudens), is an investigational anticancer agent. Irofulven rapidly inhibits DNA synthesis and blocks mitosis. It causes DNA breaks and cell death by caspasemediated apoptosis. 12 Irofulven has reversible cytostatic activity in normal cells but cytotoxic activity in tumor cells. 13 Abnormal color vision and contrast were reported after biweekly irofulven treatment in phase 1 through 3 trials.
14 Patients were initially dosed at 24 mg/m 2 every 2 weeks. Visual abnormalities occurred most frequently in individuals treated with doses exceeding 0.55 mg/kg, leading to a dosing modification by body weight to less than 0.55 mg/kg biweekly (total-dose limit, 50 mg).
Before this regimen change, our patients (4 of 18 enrolled at Massachusetts General Hospital, Boston) were enrolled in a phase 2 multicenter trial of irofulven for treatment of advanced epithelial ovarian cancer. All of our patients had progressive disease despite prior chemotherapy including carboplatin. After receiving high doses of irofulven treatment, clinical signs and symptoms of retinal cone dysfunction developed in these patients. Histopathologic and immunocytochemistry studies of one patient's postmortem retinas revealed marked cone photoreceptor pathologic features. 
REPORT OF CASES

CASE 1
A 79-year-old woman had stage III peritoneal papillary serous adenocarcinoma unamenable to surgery that continued to progress despite multiple regimens of chemotherapy including paclitaxel and carboplatin, oral etoposide, and intravenous topotecan, oral anastrozole, and liposomal doxorubicin. On July 13, 2001 , she enrolled in a phase 2 irofulven trial and received a single dose of this drug (0.6 mg/kg). Four days later, she noted significant glare and "misty" vision. Two weeks later, she reported intermittent photopsias. Ocular history included best-corrected visual acuity (VA) of 20/30 OU and cataracts. On August 4, 2001 , VA was 20/30 OU. With both eyes she identified 3 of 10 Ishihara color plates. Goldmann visual fields (GVFs) revealed dense paracentral and midperipheral scotomas ( Figure 1A) . Fundus examination showed peripapillary pigmentary changes but the macula and optic nerve appeared normal in both eyes. Dim scotopic electroretinographic (ERG) b-wave amplitudes were within the normal range for our laboratory ( sponses but otherwise remained unchanged. Later that month, acute myeloid leukemia developed and the patient died 7 weeks later. Her globes were harvested postmortem for evaluation.
CASE 2
A 71-year-old woman with a history of ovarian cancer with abdominal metastases received 3 doses of biweekly irofulven treatment (0.61-0.63 mg/kg). Two days after the last dose she awoke with dim vision, glare, and photophobia. She denied positive visual phenomena. Her VA was 20/25 OD and 20/30 OS and with both eyes she identified 8 of 8 Ishihara color plates. Her GVFs revealed paracentral and midperipheral scotomas in each eye. An ERG showed markedly abnormal cone responses with normal rod responses. Findings from the remainder of her ophthalmologic examination were normal. She stopped irofulven treatment and at 10 weeks' follow-up, her symptoms were gone, VA was 20/20 OU, and GVFs showed resolution of the scotomas in the right eye and 1 midperipheral scotoma remaining in the left eye. Her serum sample lacked antirecoverin antibodies (Charles Thirkill, PhD, written communication, August 2001). She refused a second ERG.
CASE 3
A 44-year-old woman with ovarian cancer received 3 doses of biweekly irofulven treatment (0.55-0.57 mg/kg). The day after her last dose she noted a "dark film" in both eyes, photophobia, and photopsias. Her VA was 20/25 OD and 20/20 OS and she identified 13 of 16 Ishihara color plates with the right eye and 12 of 16 with the left eye. The GVFs revealed Bjerrum scotomas in each eye. The results of the remainder of her ophthalmologic examination were unremarkable. The ERG showed markedly abnormal cone responses and normal rod responses. She refused followup; however, by telephone 2 months later she related that her symptoms had resolved.
CASE 4
A 53-year-old woman with ovarian cancer received 4 doses of biweekly irofulven treatment (0.53 mg/kg) and noted photophobia and photopsias for 4 days following the last dose. She received a fifth dose of the drug and her photophobia persisted. Visual acuity was 20/25 OU and she identified 10 of 10 Ishihara plates with both eyes. Results of the GVFs showed paracentral scotomas in the right eye and arcuate defects in the left eye. The ERG showed moderately abnormal cone responses and normal rod responses. At 1-month follow-up, VA was 20/20 OU and her scotomas had decreased in size and severity. The ERG showed modest improvement but remained slightly abnormal. 
HISTOPATHOLOGIC FINDINGS
Postmortem human eyes were obtained through Harvard Medical School, Boston, Mass, and the University of Washington, Seattle. Normal eyes (from a 76-year-old woman, 6 1 ⁄2 hours postmortem; 83-year-old woman, 6 hours postmortem; and 53-year-old man, enucleation) were processed as noted below. The eyes of patient 1 were fixed 8 hours postmortem for 4 days in a combination of 4% paraformaldehyde and 0.5% glutaraldehyde in 0.1M phosphate buffer, pH 7.3, and stored in 2% paraformaldehyde. Retinal samples (from macula and mid and far periphery) were processed in glycol methacrylate, sectioned at 4 µm, and stained with methylene blue/azure II (Richardson stain).
IMMUNOCYTOCHEMISTRY
Retina samples from patient 1 and normal retinas (macula, mid and far periphery) were processed for immunofluorescence 15 with mouse mAb 7G6 specific for cones (1:250); mouse mAb 4D2 antirhodopsin specific for rods (1:40); and rabbit antiglial fibrillary acidic protein (GFAP) specific for astrocytes and reactive Müller cells (1:750, DAKO Corp, Carpinteria, Calif ). Secondary antibodies (goat antirabbit and antimouse IgG, 1:50) were labeled (red) with Cy-3 (Jackson ImmunoResearch Laboratories, West Grove, Pa). Cell nuclei were stained (blue) with 4Ј, 6Ј-diamidino-2-phenylindole (1 µg/mL; Molecular Probes, Eugene, Ore). Control sections had primary antibody omitted. Sections were imaged with an epifluorescence microscope (Leitz DMR-B 513810; Leica Inc, Deerfield, Ill) or an inverted laser scanning confocal microscope (Zeiss LSM 510; Carl Zeiss, Thornwood, NY).
RESULTS
NORMAL RETINAS
All of the control eyes showed the same normal retinal histologic features. Cytoplasm of all cones was labeled with mAb 7G6 (Figure 3A) . Cone cell bodies were numerous in the maculas and formed a monolayer elsewhere. Cone outer segments had normal length. The retinal pigment epithelium (RPE) was filled with autofluorescent lipofuscin. Rhodopsin was localized in long, thin rod outer segments ( Figure 3B ). The GFAP was limited to astrocytes in the nerve fiber and ganglion cell layers ( Figure 3C ). Control sections had only autofluorescent RPE lipofuscin ( Figure 3D ).
RETINA OF IROFULVEN-TREATED PATIENT
Gross Pathologic Features
Anterior segments were normal but lenses had mild cortical opacities. The vitreous was clear, but peripapillary pigment was present in both eyes. The maculas had no evidence of pigmentary degeneration.
Microscopic Pathologic Features
The foveal pit had reduced cone numbers. Parafoveal photoreceptors were reduced to 3 or 4 rows (normal, 6-8) ( Figure 3E ). Cones were lost gradually toward the edge of the macula (Figures 3F-H) . All cone outer segments were shortened. No drusen or RPE abnormalities were evident. Inner nuclear and ganglion cell layers had normal neuron numbers (Figures 3E-H) . Very few peripheral cones were retained: a 1-mm length of peripheral retina contained only 2 cones ( Figure 3I) .
Rods in the parafovea ( Figure 3J ) and periphery ( Figure 3K ) had shortened outer segments and rhodopsin was abnormally delocalized to their cell bodies. However, near-normal numbers of rods were present in all regions. In addition to GFAP-positive astrocytes in the nerve fiber and ganglion cell layers, Müller cells had hypertrophied GFAP-positive processes ( Figure 3L ). Control sections had only autofluorescent RPE lipofuscin.
COMMENT Photophobia, dimmed vision, and positive visual phenomena consistent with cone dysfunction developed in these 4 patients. Three patients received doses of more than 0.55 mg/kg of irofulven while patient 4 received a 0.53-mg/kg dose. At the lower dose, patient 4 had less cone dysfunction with ERG testing. Visual symptoms developed in all 4 patients by the fourth biweekly dose. Color vision was variably affected but all had abnormal GVFs and prominent cone dysfunction on ERGs. Each had improved visual function after reduction or discontinuation of irofulven treatment. Abnormal cone ERG responses and normal rod ERG responses developed in 3 additional patients several days after the administration of irofulven. 16 The ERGs and histopathologic features of the retinas of patient 1 demonstrated that the cones were more severely affected than the rods. Foveas and maculas had marked cone loss but normal numbers of rods as well as neurons in the inner nuclear and ganglion cell layers. Remaining cones and rods had shortened outer segments. The periphery retained few cones. Hypertrophied reactive Müller cells were filled with GFAPs, a sensitive index of retinal cell death. 17 The microscopic findings correlate with the ERG abnormalities of cone cell death and outer segment shortening, most pronounced in the periphery but with significant cone cell loss in the maculas. The loss of peripheral cones may explain the midperipheral scotomas. Although the ERG remained unchanged, how did cone-mediated visual function improve in patient 1? Some viable macular cones remained but were abnormal with shortened outer segments. Following drug cessation they may have recovered some function. The ERG represents a summed response across the retina, and the flat cone response may reflect marked loss of cones throughout the periphery.
Rods were retained in normal numbers throughout the retina, although their outer segments were shortened and rhodopsin was delocalized to their cell bodies. Delocalized rhodopsin is commonly found in rods that have shortened outer segments due to diseases such as retinitis pigmentosa. 17 Altered cone metabolism may have contributed to abnormalities in the rods, but the rod damage might also be explained by the previous chemotherapy. Alternatively, irofulven may have contributed to rod damage as well. 
